GSK

GSK earns FDA approval for Jideytro

GSK won FDA approval for Jideytro (zidesamtinib), its ROS1 inhibitor for ROS1-positive non-small cell lung cancer, ahead of the September 18 deadline as part of its Nuvalent acquisition. The treatment, showing a 44% response rate in trials, positions GSK to compete in lung cancer and supports ongoing development of additional Nuvalent assets like neladalkib and ris-rez.